Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 6

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
  -   -   -   (623,327)  -   (623,327)Foreign currency translation gain  -   -   -   -   72,159   72,159 Balance as of March 31, 2025 *1,796,766  $17,332,315  $(5,011,891) $(4,065,947) $(482,841) $7,771,636 Net loss for the period  -   -   -   (616,172)  -   (616,172)#Fractional shares   (169)  (505)  -   -   -   (505)Foreign currency translation gain  -   -   -   -   367,078   367,078 Balance as of June 30, 2025 *1,796,597  $17,331,810  $(5,011,891) $(4,682,119) $(115,763) $7,522,037 

* Share activity (number of shares or both number and amount of shares) has been adjusted for the periods shown to reflect the 10-for-1 reverse stock split effected on April 7, 2025, on a retroactive basis 

# Rounding down of 169.30 fractional shares resulting from a 10-to-1 reverse stock split at a price of $2.98 per share

See accompanying notes to the condensed consolidated financial statements.

 7Table of Contents

BIONEXUS GENE LAB CORP. 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 

FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Six months ended   June 30,   2025  2024 Cash flows from operating activities:      Net (loss)/profit $(1,239,499) $95,347          Adjustments to reconcile net (loss)/profit to net cash used in operating activities:        Amortization of right-of-use asset  27,312   20,700 Allowances for expected credit losses